Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas
J. Z. Wang, V. Patil, J. Liu, H. Dogan, F. Behling, M. Skardelly, M. Tatagiba, E. Hoffman, S. Bunda, R. Yakubov, R. Kaloti, S. Brandner, A. Gao, A. Cohen-Gadol, J. Barnholtz-Sloan, , International Consortium on Meningiomas (ICOM)
This study investigates the relationship between CDKN2A mRNA expression and clinical outcomes in meningiomas, finding that high expression is associated with poorer progression-free survival and more aggressive tumor characteristics.
Acta Neuropathologica · Jul 1, 2023Peer-reviewedCancer Biology